Grass MATA MPL (Pollinex Quattro)
Grass Pollen-Induced Allergic Rhinitis
Phase IIIActive
Key Facts
Indication
Grass Pollen-Induced Allergic Rhinitis
Phase
Phase III
Status
Active
Company
About Allergy Therapeutics
Allergy Therapeutics is a mission-driven company committed to transforming lives by pioneering convenient, disease-modifying immunology treatments. Its core achievement is the development of a proprietary, aluminium-free adjuvant platform that enables ultra-short-course allergy vaccines, dramatically improving patient adherence and access. The company's strategy leverages its established commercial operations in Europe, particularly Germany, as a foundation while advancing a late-stage pipeline targeting major allergic indications like grass and peanut allergy, positioning it for significant growth in the expanding immunotherapy market.
View full company profile